Veltuzumab
Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of December 2011, it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD20 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6458H9918N1706O2026S46 |
| Molar mass | 145349.06 g·mol−1 |
  | |
This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]
In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]
See also
- CD20 antagonist
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (October 2009). "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864–71. doi:10.1182/blood-2009-06-228890. PMC 2773491. PMID 19710501.
- Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. (June 2015). "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma". British Journal of Haematology. 169 (5): 701–10. doi:10.1111/bjh.13354. PMC 7297055. PMID 25847298.
- Zibelman M, Borghaei H, Olszanski AJ (2014). "Harnessing Innate Immunity". In Dubel S, Reichert JM (eds.). Handbook of Therapeutic Antibodies (2nd ed.). John Wiley & Sons. p. 791. doi:10.1002/9783527682423.ch27. ISBN 978-3-527-68244-7.
- "FDA grants orphan drug designation to veltuzumab for ITP". HemOnc Today. Healio.com. August 4, 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.